Bimatoprost in the Treatment of Eyelash Hypotrichosis

April 2010 in “ PubMed Central ”

Simon K. Law

bimatoprost eyelash hypotrichosis telogen phase anagen phase alopecia areata radiation chemotherapy Latisse

From the encyclopedia

a synthetic prostamide used to treat eyelashes also shows promise for stimulating hair growth on scalp

autoimmune disorder causing patchy hair loss

Studysummary This abstract discusses the FDA approval of Latisse (bimatoprost) for increasing eyelash growth in patients with eyelash hypotrichosis and highlights its efficacy while noting unresolved effectiveness in certain conditions and potential side effects.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer ·

Discuss this study in the Community →

Related Research

7 / 7 results

research Therapeutic Potential of Bimatoprost for the Treatment of Eyebrow Hypotrichosis

34 citations , February 2018 in “Drug Design Development and Therapy”

This source reports that bimatoprost, a medication approved for eyelash growth, has shown efficacy in treating eyebrow hypotrichosis, suggesting it as a noninvasive, effective, and well-tolerated option for enhancing eyebrow hair.

research Bimatoprost for the Treatment of Eyelash, Eyebrow, and Scalp Alopecia

38 citations , March 2017 in “Expert Opinion on Investigational Drugs”

This review examines the potential of bimatoprost for treating various types of eyelash and eyebrow hypotrichosis, discussing its pharmacological properties but providing no new clinical results.

research Bimatoprost Solution 0.03% Topical Application to the Eyelid Margin for the Treatment of Eyelash Hypotrichosis

2 citations , February 2016 in “British Journal of Dermatology”

This study found that topical bimatoprost significantly improved eyelash growth in individuals with idiopathic and chemotherapy-induced eyelash hypotrichosis compared to a vehicle treatment.

Long-Term Safety and Efficacy of Latisse (Bimatoprost 0.03% Solution) for Treatment of Eyelash Hypotrichosis in Subjects with Chemotherapy-Induced and Idiopathic Hypotrichosis

research Long-Term Safety and Efficacy of Latisse (Bimatoprost 0.03% Solution) for Treatment of Eyelash Hypotrichosis in Subjects with Chemotherapy-Induced and Idiopathic Hypotrichosis

March 2012 in “Journal of The American Academy of Dermatology”

Latisse is safe and effective for long-term eyelash growth in people with thin eyelashes from chemotherapy or unknown causes.

Lack of Efficacy of Topical Latanoprost and Bimatoprost Ophthalmic Solutions in Promoting Eyelash Growth in Patients with Alopecia Areata

research Lack of Efficacy of Topical Latanoprost and Bimatoprost Ophthalmic Solutions in Promoting Eyelash Growth in Patients with Alopecia Areata

January 2010 in “Yearbook of Dermatology and Dermatologic Surgery”

Topical latanoprost and bimatoprost ophthalmic solutions don't help eyelash growth in patients with alopecia areata.

research Instilled Bimatoprost Ophthalmic Solution in Patients with Eyelash Alopecia Areata

30 citations , August 2009 in “Journal of the American Academy of Dermatology”

This study found that while bimatoprost was safe for 16 weeks, it was not effective for eyelash growth in patients with significant loss due to alopecia areata, though some with less loss experienced growth.

research Lack of Efficacy of Topical Latanoprost and Bimatoprost Ophthalmic Solutions in Promoting Eyelash Growth in Patients with Alopecia Areata

55 citations , March 2009 in “Journal of The American Academy of Dermatology”

This study found that latanoprost and bimatoprost, when applied cutaneously to the eyelids, did not induce appreciable eyelash regrowth in patients with alopecia areata over 16 weeks.